Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,894 across all filing types
Latest filing 2020-01-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
独立董事对第七届董事会第13次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a board meeting resolution regarding the extension of an employee stock ownership plan. It references legal and regulatory frameworks and confirms compliance and approval of the plan extension. The content is related to board/management information about corporate governance decisions rather than a full report, announcement of voting results, or financial data. The document length is short and focused on management/board opinion, fitting the Board/Management Information category.
2020-01-16 Chinese
关于筹划重大资产出售的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the progress of a major asset sale. It references a previous announcement about planning a significant asset disposal and provides updates on the ongoing restructuring process, including discussions with the counterparty and due diligence activities. The document emphasizes that the transaction is still in progress and subject to regulatory approvals, highlighting the uncertainty and the company's commitment to timely disclosure. The content is typical of a Capital/Financing Update as it relates to a major asset sale and restructuring progress rather than a full financial report or final transaction completion. The document length is short (831 characters), and it is not a report publication announcement but an update on financing-related corporate actions.
2020-01-16 Chinese
关于第一期员工持股计划展期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of the duration of the company's first employee stock ownership plan. It details board meetings, shareholder meetings, and approvals related to the extension of the plan's term. There is no financial data, earnings information, or detailed report content. The document is a formal announcement about a capital-related employee stock plan extension, which fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes involving employee stock plans.
2020-01-16 Chinese
关于子公司药品吲达帕胺片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary's pharmaceutical product passing a regulatory consistency evaluation by the National Medical Products Administration (国家药品监督管理局). It details the drug's approval status, basic information, and potential impact on the company. The document is short (922 characters) and serves as a formal public disclosure of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not an announcement of voting results, board changes, or capital changes. It fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about product approval and related corporate information that does not fit other specific categories.
2020-01-14 Chinese
关于芪苓温肾消囊颗粒获得临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about receiving a clinical trial notification from the National Medical Products Administration (国家药品监督管理局) for a new drug. It details the drug name, approval for clinical trials, drug development status, market situation, and potential impact and risks. The document is a formal public announcement regarding regulatory approval to start clinical trials, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive information about the clinical trial approval. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-01-13 Chinese
关于芪参益气滴丸新增适应症获得临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about receiving a clinical trial notification from the national drug regulatory authority for a new indication of an existing drug. It details the drug name, approval for clinical trial, drug development background, market situation, and potential impact on the company. The document is relatively short (1866 characters) and serves as a regulatory announcement about clinical trial approval rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report itself but an announcement of regulatory approval and clinical trial initiation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-01-07 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.